| Human immunodeficiency virus I infection

Isentress vs Triumeq

Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.

Deep comparison between: Isentress vs Triumeq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTriumeq has a higher rate of injection site reactions vs Isentress based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Triumeq but not Isentress, including UnitedHealthcare

Category

Isentress

Triumeq

At A Glance

RouteOral

FrequencyOnce or twice daily

ClassHIV-1 integrase strand transfer inhibitor

RouteOral

FrequencyOnce daily

ClassINSTI + dual NRTI antiretroviral combination

Indications

Human immunodeficiency virus I infection

Human immunodeficiency virus I infection

Dosing

Human immunodeficiency virus I infection (adults, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily or 400 mg twice daily orally, with or without food.

Human immunodeficiency virus I infection (adults, treatment-experienced) 400 mg twice daily orally, with or without food.

Human immunodeficiency virus I infection (adults, coadministration with rifampin) 800 mg (2 x 400 mg) twice daily orally.

Human immunodeficiency virus I infection (pediatrics >= 40 kg, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily, 400 mg twice daily, or 300 mg (3 x 100 mg) chewable tablets twice daily orally.

Human immunodeficiency virus I infection (pediatrics >= 25 kg) 400 mg film-coated tablet twice daily orally; weight-based chewable tablet dosing twice daily if unable to swallow tablet.

Human immunodeficiency virus I infection (pediatrics 3 kg to < 25 kg, >= 4 weeks of age) Weight-based dosing using chewable tablet or oral suspension twice daily orally (approximately 6 mg/kg/dose).

Human immunodeficiency virus I infection (neonates birth to 4 weeks, >= 2 kg) Weight-based oral suspension: once daily dosing (~1.5 mg/kg/dose) from birth to 1 week; twice daily dosing (~3 mg/kg/dose) from 1 to 4 weeks of age.

Human immunodeficiency virus I infection Adults: One tablet of TRIUMEQ (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once daily orally with or without food. Pediatric patients >=25 kg: One tablet TRIUMEQ once daily. Pediatric patients 6 to <10 kg: 3 tablets TRIUMEQ PD (180 mg abacavir, 15 mg dolutegravir, 90 mg lamivudine) once daily dispersed in water. Pediatric patients 10 to <14 kg: 4 tablets TRIUMEQ PD (240 mg abacavir, 20 mg dolutegravir, 120 mg lamivudine) once daily dispersed in water. Pediatric patients 14 to <20 kg: 5 tablets TRIUMEQ PD (300 mg abacavir, 25 mg dolutegravir, 150 mg lamivudine) once daily dispersed in water. Pediatric patients 20 to <25 kg: 6 tablets TRIUMEQ PD (360 mg abacavir, 30 mg dolutegravir, 180 mg lamivudine) once daily dispersed in water. Screen for HLA-B*5701 allele and test for HBV infection before initiating. Adjust dolutegravir to 50 mg twice daily when coadministered with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin.

Contraindications

—

Presence of HLA-B*5701 allele
Prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
Concomitant use with dofetilide
Moderate or severe hepatic impairment

Drug Interactions

895View drug interactions

1237View drug interactions

Adverse Reactions

Most common (>=2%) Headache, insomnia, nausea, dizziness, fatigue.

Serious Myopathy, rhabdomyolysis, hepatitis, hepatic failure, depression including suicidal ideation and behaviors, nephrolithiasis, renal failure, hypersensitivity.

Postmarketing Thrombocytopenia, diarrhea, hepatic failure, rhabdomyolysis, cerebellar ataxia, anxiety, paranoia.

Most common (>=2%) Insomnia, headache, fatigue, nausea, diarrhea

Serious Serious and sometimes fatal hypersensitivity reaction with abacavir, exacerbations of hepatitis B, hepatotoxicity, lactic acidosis and severe hepatomegaly with steatosis, immune reconstitution syndrome, myocardial infarction

Postmarketing Aplastic anemia, anemia, lymphadenopathy, splenomegaly, stomatitis, pancreatitis, acute liver failure, sensitization reactions including anaphylaxis and urticaria, weight increase, hyperlactemia, CPK elevation, muscle weakness, myalgia, rhabdomyolysis, peripheral neuropathy, seizures, anxiety, alopecia, erythema multiforme, suspected Stevens-Johnson syndrome, toxic epidermal necrolysis

Pharmacology

Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication, preventing integration of unintegrated linear HIV-1 DNA into the host cell genome; it is eliminated primarily via UGT1A1-mediated glucuronidation and does not inhibit or induce cytochrome P450 enzymes.

TRIUMEQ and TRIUMEQ PD are fixed-dose combinations of three HIV-1 antiretroviral agents: dolutegravir (an integrase strand transfer inhibitor that blocks HIV replication by binding to the integrase active site and inhibiting the strand transfer step), abacavir (a nucleoside analogue that is converted to carbovir triphosphate which inhibits HIV-1 reverse transcriptase by competing with dGTP and incorporating into viral DNA), and lamivudine (a nucleoside analogue phosphorylated to lamivudine triphosphate which inhibits reverse transcriptase via DNA chain termination).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Isentress